INDP INDP
Company Profile ↓Company Overview
INDP (INDP) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -81.78% |
| 6 Months: | -28.11% |
| 3 Months: | -36.36% |
| 1 Month: | -50.19% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 84.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -2.90M | -1.55M | -613.98K | -528.64K | -3.37M | -3.40M | -3.87M | -3.55M | -4.46M | -3.50M | -4.25M | -3.94M | -4.11M | -3.14M | -4.57M | -4.46M | -2.65M | -2.16M |
| Net Income | -558.58K | -712.62K | -1.54M | -612.42K | -515.48K | -3.37M | -3.37M | -3.84M | -3.47M | -4.25M | -3.25M | -3.92M | -3.81M | -4.02M | -3.07M | -4.53M | -5.23M | -2.98M | -2.54M |
| Diluted EPS | - | - | - | - | - | - | - | -0.46 | -0.42 | -0.51 | -0.39 | -0.47 | -0.45 | -13.16 | -9.04 | -9.11 | -9.09 | -2.98 | -0.23 |
| R&D Expense | - | 1.27M | 1.35M | 489.72K | 391.12K | 697.67K | 1.30M | 1.51M | 1.61M | 1.88M | 1.48M | 2.23M | 1.59M | 1.71M | 1.47M | 2.81M | 2.17M | 1.52M | 491.13K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -3.60M | -7.73M | -14.91M | -16.38M | -15.37M | -19.83M |
| Net Income | -3.58M | -7.71M | -14.32M | -15.42M | -15.02M | -20.85M |
| Diluted EPS | - | - | -1.73 | -1.83 | -44.96 | -21.58 |
| R&D Expense | 2.66M | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.78M | 40.58M | 28.06M | 14.92M | 7.34M | 9.31M |
| Total Equity | 3.21M | -237.70K | 35.90M | 24.63M | 12.08M | 3.94M | 3.15M |
| Cash & Equivalents | - | 1.64M | 39.13M | 9.63M | 13.36M | 5.79M | 8.51M |
| Total Liabilities | - | 2.02M | 4.68M | 3.43M | 2.85M | 3.39M | - |
| Current Liabilities | - | 2.02M | 4.60M | 3.43M | 2.77M | 3.39M | 6.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.32M | -11.29M | -13.08M | -13.41M | -12.32M | -14.82M |
| Investing Cash Flow | - | 447.75K | -16.43M | 17.14M | - | - |
| Financing Cash Flow | 1.16M | 48.34M | - | - | 4.75M | 17.54M |
| Capital Expenditure | - | -3.85K | - | - | - | - |
| Free Cash Flow | - | -11.29M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 1,507.8% | -21.5% | -58.2% | -127.7% | -380.8% | -661.5% |
| ROCE % | 1,514.2% | -21.5% | -60.5% | -134.8% | -389.5% | -629.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INDP
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPUGNJaklaZkdmU2EzLWh5dUdGdWxvb1dZejk2MU5oQ2tnWGxvQTNGWXQwTlVjOE5iUmFseWgwODJSaFFmcWVTN3lManBqSmxRaDFpRWQweWxUcURFazhYZlNhbkJfZUtOS0dvb0tXekFlSTZQLWVZanhvMEcwcm14UXRySWVkWGhVanI4SW…
Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZmd0cXItRlItNjVwcTByX1hYRU5mWkE4M0lHSTdqblRDX3dLWVVQQWpBbTFUWHpTOTFxeXByZXFpZ3BpMmFWNzNDNkNOeElZVFhXbXRDSkdEWG55djBCUXBGcGZPcU93NUttZmFZUXdFVXhqMF9jMnByal9JaUZBVDQ3amVJbHJTRkRBT0…
Why Did INDP Stock Gain 12% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOeDFJT2t5R2Jxc0hPR1h6OEJnMmI0N0g0SkV2YUF6Z2k3eFh6TDJocDFQd1ZoTGhGZ3Q2aC1DSmt1M25OVmJ0ZnV1MFN6alRRUVcydDRGdWYzZ0VJX2xCQzd5YW0zODJmNXVNUEFTY0ZwYjhLQVBhb1ZTaEtOb01SWGtmRkdfWklTV1NNd3…
Indaptus Therapeutics, Inc. Revenue Breakdown – NASDAQ:INDP - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5sTDV3eVlSOENHUXRuTmdQQUpLUkpHQkVyM3dRMlR5ZXI4OHRCcFJHOFEwdE05ZXNNYUlpLWxhdVBfUnFIbTZtS042S0NmbmRISkRIem5LQmxBQnlEamprejRHX05XZmh2c0F2djlrOE9rck0xU1NJ?oc=5" target="_blank">Indaptu…
INDP|Indaptus Therapeutics Inc|Price:1.290|Chg%:-0.150 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5JdW1ObFpILXlxMFZ4S1lPTjJURjNfRjVhd1pFeGJ4MXl6b01EenA3R0tvS2lTVTB4SHo3SlkwWjh5WDdHSlo0aVd0UElkaS1uRUdXMTRtSXd6dw?oc=5" target="_blank">INDP|Indaptus Therapeutics Inc|Price:1.290|Ch…
Indaptus Therapeutics (INDP) Q3 2025 earnings summary - Quartr
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5UdkZVRFNFb1ZkNmdzaW9uY1RocmVJSjJSdGtvT25EUTQ0VEVpQjlCV21CVURJQ1BVeUZ0enZyZkYtREVnX1VJR2RoSnoyUG5SUG9xVndWblhGUWJjbHRPcUc2eE5WaVdxRWJpMGotM2JhdWRNM2hQaw?oc=5" target="_blank">Indap…
INDP — Frequently Asked Questions
What is the current share price of INDP?
As of 2026-08-05 17:25 PDT, INDP trades at $1.33 on NASDAQ/NYSE. Its 52-week range is $1.06 to $8.44.
What is the P/E ratio of INDP?
INDP trades at a trailing price-to-earnings (P/E) ratio of -0.06.
Is INDP a good stock to buy?
This page provides a data-driven analysis of INDP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.